JP2016537410A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016537410A5 JP2016537410A5 JP2016551080A JP2016551080A JP2016537410A5 JP 2016537410 A5 JP2016537410 A5 JP 2016537410A5 JP 2016551080 A JP2016551080 A JP 2016551080A JP 2016551080 A JP2016551080 A JP 2016551080A JP 2016537410 A5 JP2016537410 A5 JP 2016537410A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- composition
- oligosaccharide
- gos
- management
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 11
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 4
- 150000003271 galactooligosaccharides Chemical class 0.000 claims 3
- 229920001542 oligosaccharide Polymers 0.000 claims 3
- 150000002482 oligosaccharides Polymers 0.000 claims 3
- 230000000529 probiotic Effects 0.000 claims 3
- 239000006041 probiotic Substances 0.000 claims 3
- 235000018291 probiotics Nutrition 0.000 claims 3
- 229940107161 Cholesterol Drugs 0.000 claims 2
- 230000001580 bacterial Effects 0.000 claims 2
- 235000012000 cholesterol Nutrition 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 235000013406 prebiotics Nutrition 0.000 claims 2
- 206010012601 Diabetes mellitus Diseases 0.000 claims 1
- 210000001035 Gastrointestinal Tract Anatomy 0.000 claims 1
- 240000006024 Lactobacillus plantarum Species 0.000 claims 1
- 229940072205 Lactobacillus plantarum Drugs 0.000 claims 1
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 102000005936 beta-Galactosidase Human genes 0.000 claims 1
- 108010005774 beta-Galactosidase Proteins 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 235000015872 dietary supplement Nutrition 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000006911 enzymatic reaction Methods 0.000 claims 1
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims 1
- 244000005700 microbiome Species 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
Claims (10)
- 微生物によって生成されたオリゴ糖を含むプレバイオティクス組成物であって、前記オリゴ糖が、所定のプロバイオティクス細菌株に選択的であること、および前記所定のプロバイオティクス細菌株によって逆酵素反応により生成することができることを特徴とし、
前記所定のプロバイオティクス細胞株が、ラクトバチルス・プランタルム(Lactobacillus plantarum)を含み、前記酵素がβ−ガラクトシダーゼであり、前記オリゴ糖がガラクトオリゴ糖(GOS)を含み、前記GOSが、β1−4結合を含む、プレバイオティクス組成物。 - 被包されている、請求項1に記載の組成物。
- 身体の胃腸管環境を通過し、その機能的特性を保持できるようにするための賦形剤または担体化合物をさらに含む、請求項1から2のいずれかに記載の組成物。
- 飲むことのできる液体の形態であり、かつ/または固体もしくは液体食料品と混合することができる、請求項1から3のいずれか一項に記載の組成物。
- 薬品(medicament)として使用するための、請求項1から3のいずれか一項に記載の組成物。
- 栄養補助食品として使用するための、請求項1から3のいずれか一項に記載の組成物。
- コレステロールの管理もしくは高コレステロールの処置に使用するための、請求項1から3のいずれか一項に記載の組成物。
- メタボリック症候群の管理もしくは処置に使用するための、請求項1から3のいずれか一項に記載の組成物。
- 体重管理に使用するための、請求項1から3のいずれか一項に記載の組成物。
- 糖尿病の処置に使用するための、請求項1から3のいずれか一項に記載の組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1319539.1A GB201319539D0 (en) | 2013-11-05 | 2013-11-05 | Composition & methods of screening |
GB1319539.1 | 2013-11-05 | ||
PCT/GB2014/053303 WO2015067949A1 (en) | 2013-11-05 | 2014-11-05 | Composition & methods of screening |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019109634A Division JP2019206528A (ja) | 2013-11-05 | 2019-06-12 | 組成物およびスクリーニング方法 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2016537410A JP2016537410A (ja) | 2016-12-01 |
JP2016537410A5 true JP2016537410A5 (ja) | 2018-06-14 |
JP6890972B2 JP6890972B2 (ja) | 2021-06-18 |
Family
ID=49767702
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016551080A Active JP6890972B2 (ja) | 2013-11-05 | 2014-11-05 | 組成物およびスクリーニング方法 |
JP2019109634A Pending JP2019206528A (ja) | 2013-11-05 | 2019-06-12 | 組成物およびスクリーニング方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019109634A Pending JP2019206528A (ja) | 2013-11-05 | 2019-06-12 | 組成物およびスクリーニング方法 |
Country Status (7)
Country | Link |
---|---|
US (2) | US9913857B2 (ja) |
EP (2) | EP3065572B1 (ja) |
JP (2) | JP6890972B2 (ja) |
AU (2) | AU2014345344B2 (ja) |
CA (2) | CA2929815C (ja) |
GB (2) | GB201319539D0 (ja) |
WO (1) | WO2015067949A1 (ja) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105407728A (zh) | 2013-07-21 | 2016-03-16 | 霍勒拜欧姆公司 | 用于微生物组表征、监测和治疗的方法和系统 |
AU2015341571A1 (en) * | 2013-11-05 | 2017-05-18 | Optibiotix Limited | Prebiotic composition and its method of production |
GB201319531D0 (en) * | 2013-11-05 | 2013-12-18 | Optibiotix Health Ltd | Composition & methods of screening |
GB201319539D0 (en) * | 2013-11-05 | 2013-12-18 | Optibiotix Health Ltd | Composition & methods of screening |
WO2016070151A1 (en) | 2014-10-31 | 2016-05-06 | Whole Biome. Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
GB201509023D0 (en) * | 2015-05-27 | 2015-07-08 | Optibiotix Ltd | Compositions and methods of production thereof |
GB201509021D0 (en) * | 2015-05-27 | 2015-07-08 | Optibiotix Ltd | Methods of screening |
EP3491382A4 (en) * | 2016-07-29 | 2020-04-08 | Isothrive LLC | OPTIMIZED INDIVIDUALIZED PREBIOTIC COMPOSITIONS |
JP2020532515A (ja) | 2017-08-30 | 2020-11-12 | ペンデュラム セラピューティクス, インコーポレイテッド | マイクロバイオーム関連障害の処置のための方法および組成物 |
EP4056052A1 (en) * | 2021-03-12 | 2022-09-14 | Biogaia AB | Gos pre-conditioning l. reuteri and gos in final formulation |
EP4056053A1 (en) * | 2021-03-12 | 2022-09-14 | Biogaia AB | Pre-conditioning of l. reuteri |
WO2024013211A1 (en) * | 2022-07-12 | 2024-01-18 | Novozymes A/S | Method for providing relief from lactose induced abdominal discomfort |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69600525T2 (de) | 1996-12-23 | 1998-12-10 | Sitia Yomo Spa | Lyophilisierte, lebende Bakerien enthaltende Nahrungszusammensetzung |
GB0303716D0 (en) * | 2003-02-18 | 2003-03-19 | Mars Uk Ltd | Food product and process |
CA2652517A1 (en) | 2006-06-13 | 2007-12-21 | Nestec S.A. | Prevention and treatment of otitis media with non-pathogenic bacterial strains |
US20080254011A1 (en) * | 2007-04-11 | 2008-10-16 | Peter Rothschild | Use of selected lactic acid bacteria for reducing atherosclerosis |
WO2010060722A1 (en) | 2008-11-03 | 2010-06-03 | Nestec S.A. | A nutritional composition comprising probiotics and improving sleep patterns |
EP2216036A1 (en) | 2009-02-10 | 2010-08-11 | Nestec S.A. | Lactobacillus rhamnosus NCC4007, a probiotic mixture and weight control |
PL2419114T5 (pl) * | 2009-05-01 | 2019-09-30 | Uas Laboratories Llc | Kompozycje bakteryjne do profilaktyki i leczenia choroby degeneracyjnej |
US20110117629A1 (en) * | 2009-11-19 | 2011-05-19 | Family Medicine Interantional Co., Ltd. | Lactobacillus plantarum bb9 capable of adhering to gastrointestinal tract and cholesterol removal |
CN102985105B (zh) | 2010-01-19 | 2016-03-09 | 雅培制药有限公司 | 包含合生元的营养配方 |
US20120263696A1 (en) | 2011-04-14 | 2012-10-18 | Stefan Roos | Indirect Substrates for Microorganisms Metabolizing 1,2-Propanediol |
GB201319539D0 (en) * | 2013-11-05 | 2013-12-18 | Optibiotix Health Ltd | Composition & methods of screening |
-
2013
- 2013-11-05 GB GBGB1319539.1A patent/GB201319539D0/en not_active Ceased
-
2014
- 2014-11-05 US US15/034,420 patent/US9913857B2/en active Active
- 2014-11-05 CA CA2929815A patent/CA2929815C/en active Active
- 2014-11-05 WO PCT/GB2014/053303 patent/WO2015067949A1/en active Application Filing
- 2014-11-05 EP EP14806047.8A patent/EP3065572B1/en active Active
- 2014-11-05 CA CA3028210A patent/CA3028210C/en active Active
- 2014-11-05 JP JP2016551080A patent/JP6890972B2/ja active Active
- 2014-11-05 EP EP21153623.0A patent/EP3892116A1/en active Pending
- 2014-11-05 AU AU2014345344A patent/AU2014345344B2/en active Active
-
2015
- 2015-05-05 GB GBGB1507664.9A patent/GB201507664D0/en not_active Ceased
-
2018
- 2018-02-21 US US15/901,637 patent/US10493093B2/en active Active
- 2018-07-26 AU AU2018208701A patent/AU2018208701B2/en active Active
-
2019
- 2019-06-12 JP JP2019109634A patent/JP2019206528A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2016537410A5 (ja) | ||
Le Doare et al. | Mother’s milk: a purposeful contribution to the development of the infant microbiota and immunity | |
Indira et al. | Bioactive molecules of probiotic bacteria and their mechanism of action: a review | |
NZ601141A (en) | Nutritional formulas containing synbiotics | |
NZ612386A (en) | Synbiotic combination of probiotic and human milk oligosaccharides to promote growth of beneficial microbiota | |
MY187609A (en) | Human milk oligosaccharides to ameliorate symptoms of stress | |
JP2012520325A5 (ja) | ||
PH12016501953A1 (en) | Pediatric nutritional composition with human milk oligosaccharides, prebiotics and probiotics | |
WO2012024638A3 (en) | Compositions and methods for treating obesity by characterizing and restoring mammalian bacterial microbiota | |
JP2015523321A5 (ja) | ||
Wang et al. | Characteristics of probiotic preparations and their applications | |
Kvakova et al. | Co-encapsulated synbiotics and immobilized probiotics in human health and gut Microbiota modulation | |
WO2010146568A3 (en) | Bifidobacteria for treating diabetes and related conditions | |
JP2017537156A5 (ja) | ||
JP2016529309A5 (ja) | ||
WO2014006261A3 (es) | Micropartículas para encapsulación de probióticos, su obtención y usos | |
CL2008001993A1 (es) | Uso de bacterias probioticas lactobacillus y bifidobacterium en la preparacion de una composicion para normalizar la concentracion de glucosa plasmatica, aumentar la respuesta a insulina y prevenir la diabetes gestacional. | |
MY158816A (en) | Probiotics for reduction of risk of obesity | |
MX2009009442A (es) | Probioticos para mejorar la microbiota intestinal. | |
JP2013139462A5 (ja) | ||
JP2013177448A5 (ja) | ||
MX2013002171A (es) | Producto simbiotico. | |
WO2009112361A3 (en) | Synbiotic mixture | |
JP2019508486A5 (ja) | ||
Gulliver et al. | the future of microbiome‐based therapeutics |